loading
前日終値:
$21.51
開ける:
$21.57
24時間の取引高:
192.19K
Relative Volume:
0.87
時価総額:
$1.05B
収益:
-
当期純損益:
$-85.21M
株価収益率:
-11.15
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
-0.05%
1か月 パフォーマンス:
+4.57%
6か月 パフォーマンス:
-12.68%
1年 パフォーマンス:
+19.78%
1日の値動き範囲:
Value
$20.89
$22.12
1週間の範囲:
Value
$20.23
$22.69
52週間の値動き範囲:
Value
$15.96
$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name
名前
Enliven Therapeutics Inc
Name
セクター
Healthcare (1166)
Name
電話
720-647-8519
Name
住所
6200 LOOKOUT ROAD, BOULDER
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
ELVN's Discussions on Twitter

ELVN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ELVN
Enliven Therapeutics Inc
21.07 1.05B 0 -85.21M -68.53M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-13 開始されました BTIG Research Buy
2024-09-09 開始されました H.C. Wainwright Buy
2024-06-11 開始されました Robert W. Baird Outperform
2024-04-09 開始されました Mizuho Buy
2023-03-29 開始されました Jefferies Buy

Enliven Therapeutics Inc (ELVN) 最新ニュース

pulisher
Mar 26, 2025

Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 25, 2025
pulisher
Mar 23, 2025

HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Enliven Therapeutics chief scientific officer sells $257,575 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 20, 2025

Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

(ELVN) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 20, 2025
pulisher
Mar 20, 2025

Lifesci Capital Issues Optimistic Forecast for ELVN Earnings - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK

Mar 19, 2025
pulisher
Mar 15, 2025

Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com

Mar 15, 2025
pulisher
Mar 14, 2025

Enliven grew fourth-quarter R&D spending with trials underway - BizWest

Mar 14, 2025
pulisher
Mar 14, 2025

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value the Markets

Mar 14, 2025
pulisher
Mar 14, 2025

Enliven Therapeutics Reports 2024 Financial Results - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune

Mar 13, 2025
pulisher
Mar 13, 2025

Enliven Therapeutics Inc. (ELVN) reports earnings - Quartz

Mar 13, 2025
pulisher
Mar 13, 2025

Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

ENLIVEN THERAPEUTICS Earnings Results: $ELVN Reports Quarterly Earnings - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Enliven Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Earnings Flash (ELVN) Enliven Therapeutics Posts Q4 Loss $-0.46 Per Share -March 13, 2025 at 04:12 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 11, 2025

Enliven Therapeutics COO Anish Patel sells $142,936 in stock - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Enliven Therapeutics COO Anish Patel sells $142,936 in stock By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 09, 2025

(ELVN) Investment Analysis and Advice - Stock Traders Daily

Mar 09, 2025
pulisher
Mar 06, 2025

Enliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Sells 2,488 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 05, 2025
pulisher
Mar 03, 2025

Enliven Therapeutics CFO Sells Shares - TradingView

Mar 03, 2025
pulisher
Mar 01, 2025

Enliven Therapeutics CFO sells $22,524 in stock - MSN

Mar 01, 2025
pulisher
Feb 25, 2025

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Longview News-Journal

Feb 25, 2025
pulisher
Feb 25, 2025

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference – Company Announcement - Financial Times

Feb 25, 2025
pulisher
Feb 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap DownHere's Why - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

(ELVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Feb 16, 2025
pulisher
Feb 14, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Enliven Therapeutics COO Anish Patel sells $146,205 in stock - MSN

Feb 13, 2025
pulisher
Feb 11, 2025

Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Enliven Therapeutics COO Anish Patel sells $146,205 in stock By Investing.com - Investing.com South Africa

Feb 10, 2025
pulisher
Feb 05, 2025

Trend Tracker for (ELVN) - Stock Traders Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating - TipRanks

Feb 05, 2025
pulisher
Feb 04, 2025

SG Americas Securities LLC Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Feb 04, 2025
pulisher
Feb 04, 2025

Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data - TipRanks

Feb 04, 2025
pulisher
Feb 02, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares - MarketBeat

Feb 02, 2025
pulisher
Jan 31, 2025

Enliven Therapeutics CFO sells $70,177 in stock - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Jan 31, 2025

Enliven Therapeutics Inc (ELVN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Enliven Therapeutics Inc (ELVN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Mar 24 '25
Option Exercise
2.48
1,000
2,480
24,000
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Mar 24 '25
Sale
22.50
1,000
22,504
23,000
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
Mar 19 '25
Sale
20.61
12,500
257,575
1,002,688
Kintz Samuel
PRESIDENT AND CEO
Mar 17 '25
Sale
20.83
12,500
260,320
990,392
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):